Narcolepsy Drugs Market was US$ 5.95 Billion in 2030, and it is expected to grow by 8.01% from 2023 to 2030 ⅼ Renub Research

Narcolepsy is a sleep disorder disease that concerns a person’s capability to manage their sleep-wake cycles. It is a severe neurological disorder that causes sudden, unmanageable sleep attacks and makes patients day to day activities difficult. Despite having rested after waking up, people affected with narcolepsy may encounter extreme sleepiness throughout the day.

Many people who are affected by narcolepsy also experience uneven and interrupted sleep during the night. Narcolepsy can severely affect the daily activities of the patients who are affected by this disease. People who are severely suffering from narcolepsy may fall asleep in the middle of any activity, for example, talking, driving, or eating.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=narcolepsy-drugs-market-p.php

Cataplexy is a symptom of sudden muscle weakness while awake that makes a patient limp or unable to move. Narcolepsy is an incurable disease, but symptoms can be managed to improve over time with proper medications and lifestyle changes. The rising stress levels among individuals accordingly lead to a stressful lifestyle. An increase in the consumption of tobacco, alcohol, and other harmful addictive substances is going to aggravate the risk of narcolepsy further.

Factors to Drive the Growth

The Narcolepsy drugs Market is forecasted to rise due to growth in disposable income, majorly in India and China, and awareness about their benefits. Market growth is also driven by the rising prevalence of the disease, advanced research and development activities and investments, and the intro of new therapeutic drugs.

Sodium oxybate, clinically known as gamma-hydroxybutyrate (GHB), is the most recommended drug. It immensely helps in improving the lifestyles of the affected ones. This drug works by controlling sleep patterns and reducing cataplexy incidents. Sodium oxybate has gained popularity among healthcare companies and patients due to its special agent of activity. This drug is tailored to address complex medical conditions of narcolepsy. The Food and Drug Administration (FDA) authorized Lumryz, a sodium oxybate-based medication, as a treatment for cataplexy and excessive daytime sleepiness in adult narcolepsy patients in May 2023.

 

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Contact Us:

Renub Research         

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com